Research-based global biopharmaceutical company AbbVie (NYSE:ABBV) and pharmaceutical company Allergan (NYSE:AGN) revealed on Monday that Allergan has signed definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase) in the first-quarter 2020.
The agreements are reportedly part of the ongoing regulatory approval process for AbbVie's acquisition of Allergan subject to receipt of required regulatory approvals and other closing conditions, including the FTC and European Commission approvals.
Under the terms of an agreement, AstraZeneca (NYSE:AZN) will acquire brazikumab, an investigational IL-23 inhibitor in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.
Pursuant to the agreement, Nestle (Swiss:NESN) will acquire and take full operational ownership of Zenpep upon closing and customary transition support from Allergan. Zenpep is a treatment available in the US for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. Nestle will be acquiring Viokace, another pancreatic enzyme preparation, as part of the same transaction.
Both the acquisitions of brazikumab and Zenpep are contingent upon receipt of US Federal Trade Commission and European Commission approval, closing of AbbVie's pending acquisition of Allergan as well as the satisfaction of other customary closing conditions.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera